1. Introduction {#s0005}
===============

Hepatitis C virus (HCV) infects \>200 million people worldwide. Approximately 60%--80% of HCV infections progress into chronic diseases, including steatosis, cirrhosis, and liver cancer.[@b0005] The standard of care for the treatment for HCV infection include pegylated interferon-α (IFN-α), ribavirin, and IFN-free direct-acting antiviral (DAA) agents. The recent use of DAA, including protease inhibitors and polymerase inhibitors, have advanced the efficacy of anti-HCV agents to almost cure for most HCV genotypes.[@b0010] However, DAA treatment is not suitable for patients with advanced infection that are with a high risk of liver failure, development of hepatocellular carcinoma, or death.[@b0010] In addition, patients with a prior history of hepatocellular carcinoma and who have been treated with DAA for HCV infection have an unexpected high recurrence rate of liver cancer than previously predicted, with the recurrence rate of \>40% in some subgroups.[@b0015] In addition, the emerging resistance and high cost of DAA treatment is still a high barrier that hinders broad access to patients.[@b0020]

In addition to the HCV genome-encoded nonstructural (NS) proteins, host factors play essential functions in every step of the HCV life cycle. Drugs targeted at host factors, cellular components, or functions involved in viral life cycle are emerging as new therapeutic options for the management of HCV infection, especially potential agents to be used in combination with DAA.[@b0025] For example, small molecule inhibitors that inhibit the peptidyl-prolyl *cis*/*trans* isomerase activity of cyclophilins can suppress replication of HCV, human immunodeficiency virus (HIV), and coronaviruses.[@b0025] Our previous study suggested that heat shock cognate protein 70 (Hsc70) binds to the 3′ untranslated region (NTR) and is involved actively in HCV replication.[@b0030] Allosteric regulation of the ATPase activity of Hsc70 by tylophorine analogs DCB-3503 and *rac*-cryptopleurine perturbed translation of HCV RNA, which lead to inhibition of HCV replication.[@b0030] *rac*-Cryptopleurine analogs exhibited inhibitory activities against several diseases, including cancer,[@b0035], [@b0040] arthritis,[@b0045] inflammation,[@b0050] and dysentery.[@b0055] We designed and synthesized a series of E-ring modified *rac-*cryptopleurine analogs,[@b0035], [@b0050] which showed improved anti-cancer activity than the parent compounds.[@b0035], [@b0050] We recently reported that tylophorine analog DCB-3503 perturbed translation of HCV RNA via disruption of the replication complex, especially the binding between NS5A, NS5B, HCV RNA, and heat shock cognate protein 70 (Hsc70).[@b0030] Despite the potency *rac*-cryptopleurine exhibited, the selection index of this compound to HCV replication and cytotoxicity is low (IC~50~/EC~50~ is only \<4 fold, [Table 1](#t0005){ref-type="table"} ). Modification of the E-ring of *rac*-cryptopleurine also changed the potency and inhibitory effect on NF-κB, AP-1, and CRE signaling pathways.[@b0060] Therefore, modification on the E-ring has the potential to yield compounds with improved pharmacological profiles than *rac*-cryptopleurine. In this study, we determined the structural-activity relationship (SAR) correlations of E-ring modified *rac-*cryptopleurine analogs on anti-HCV activity and modulation of chaperone activity of Hsc70, aiming to provide insight into the structures that we could further modify to design new compound(s) having anti HCV activity with decreasing cytotoxicity.Table 1Activity of cryptopleurine analogs on HCV and HBV replication, and cytotoxicity to Huh-luc/neo-ET and HepG2.2.15 cells. Results shown are calculated from three independent experiments and depicted as mean ± SD. Chemical structures are shown in [Fig. 1](#f0005){ref-type="fig"}.HCV (Huh-luc/neo-ET, 72 h)HBV (HepG2.2.15, 6 d)EC~50~ (nM) [a](#tblfn1){ref-type="table-fn"}IC~50~ (nM)[b](#tblfn2){ref-type="table-fn"}IC~50~/EC~50~EC~10~ (nM)[c](#tblfn3){ref-type="table-fn"}IC~50~ (nM)*rac*-cryptopleurine0.6 ± 0.12.0 ± 0.1^6^3.33\>306.3 ± 1.2DCB-350331.5 ± 7.091.0 ± 11.0^6^2.89\>30098.9 ± 7.2YXM-1094.9 ± 4.742.1 ± 1.28.59\>26134.0 ± 28.0YXM-1101.4 ± 0.25.0 ± 4.13.57\>5.549.0 ± 15.0YXM-139246.1 ± 92.23.75 µM15.24\>3 µM1.6 ± 0.2 μMYXM-1403.0 ± 1.621.3 ± 8.87.10\>25258.0 ± 70.0YXM-66183.4 ± 61.11 µM5.46\>5001.4 ± 0.2 μMYXM-82650.6 ± 46.41 µM1.54\>5001.1 ± 0.2 μMYXM-8352.3 ± 7.10.5 ± 18.55.75\>1 µM2.7 ± 0.2 μMYXM-93750.2 ± 34.81 µM1.33\>3000.82 ± 0.13 μMYXM-14216.7 ± 3.8120.1 ± 17.07.19\>3004.0 ± 0.2 μMYXM-1013.75 µM4 µM1.07\>9002.4 ± 0.4 μM[^1][^2][^3]

2. Results and discussion {#s0010}
=========================

Previously, we established relationships between the anti-cancer activity and protein synthesis inhibitory effect of tylophorine and *rac*-cryptopleurine analogs with variously substituted and sized E-rings.[@b0060], [@b0065] In this study, we focused on the effect of how E-ring modifications affect the anti-HCV activity. The modifications include addition of hydroxyl group with different configurations on the E-ring, enlargement of the E-ring, and heteroatom incorporation into the E-ring ([Fig. 1](#f0005){ref-type="fig"} ). The anti-HCV activity was determined in Huh-luc/neo-ET cells harboring the HCV genotype 1b replicon. Among these analogs, compounds YXM-109, YXM-110, and YXM-140 maintained significant anti-HCV activity (EC~50~ 1.4--4.9 nM) comparable or only slightly lower than that of *rac*-cryptopleurine (EC~50~ 0.6 nM) ([Table 1](#t0005){ref-type="table"}). However, the selectivity ratio of HCV activity (EC~50~) to cytotoxicity (IC~50~) increased for YXM-109 and YXM-140 (increased IC~50~/EC~50~ ratio, [Table 1](#t0005){ref-type="table"}). A change of the 12-hydroxyl moiety from a *beta*- (YXM-140) to an *alpha-*orientation (YXM-139) led to significantly decreased anti-HCV activity and cytotoxicity ([Table 1](#t0005){ref-type="table"}). On the other hand, the same change with a 13-hydroxyl group increased anti-HCV activity and cytotoxicity (compare YXM-109 with YXM-110).Fig. 1Schematic description of the SAR of cryptopleurine analogs with E-ring modifications on anti-HCV activity.

Incorporation of a secondary nitrogen atom at C-13 (YXM-66) or an oxygen atom at position-12 (YXM-82) in a six-membered E-ring caused significant loss of anti-HCV activity ([Table 1](#t0005){ref-type="table"}). The presence of a tertiary nitrogen atom substituted with a dimethylamino group at position-12 (YXM-101) further decreased the anti-HCV activity ([Table 1](#t0005){ref-type="table"}). Enlargement to a seven-membered E-ring containing an additional carbon (YXM-83) or oxygen (YXM-142) decreased the anti-HCV activity compared with *rac*-cryptopleurine ([Table 1](#t0005){ref-type="table"}). Compound YXM-93 with only a five-membered E-ring essentially lost anti-HCV activity ([Table 1](#t0005){ref-type="table"}). In fact, any anti-HCV activity exhibited by YXM-82, YXM-93, and YXM-101 was primarily due to their cellular cytotoxicity, considering the marginal difference between their EC~50~ and IC~50~ values (low ratio of IC~50~/EC~50~, [Table 1](#t0005){ref-type="table"}).

Hsc70 is actively involved in the replication of both HCV[@b0030], [@b0070] and hepatitis B virus (HBV).[@b0075] The C-terminal substrate binding domain of Hsc70 is an essential sequence for replication of both wide-type and lamivudine-resistant HBV,[@b0075], [@b0080] and reduced replication of HBV DNA results from a decreased expression level of Hsc70, such as caused by RNA interference[@b0085] or treatment with natural product oxymatrine,[@b0075] its analogs,[@b0090] or *N*-substituted matrinic acid derivatives.[@b0095] However, the cellular machinery required for replication of HBV, a partial double strand DNA virus, is distinct from that of HCV.[@b0100] Treatment with *rac*-cryptopleurine or YXM-110 did not affect the expression level of Hsc70 for up to 72 h ([Fig. 2](#f0010){ref-type="fig"} A). We next assessed the anti-HBV activity of cryptopleurine analogs in HBV genome-integrated HepG2.2.15 cells ([Table 1](#t0005){ref-type="table"}). The compounds' EC~10~ values against HBV were higher than their EC~50~ values against HCV ([Table 1](#t0005){ref-type="table"}), suggesting that cryptopleurine analogs specifically inhibit HCV replication.Fig. 2The effect of cryptopleurine analogs on ATPase activity of Hsc70. (A) The expression level of NS3, NS5A, and Hsc70 under treatment with *rac*-cryptopleurine and YXM-110 in different time were analyzed by Western blot. (B) Ten micromole of each cryptopleurine analogs were added in the Hsc70 ATPase activity assay. The concentration of ADP produced was analyzed and calculated based on the area under the curve according to the standard curve generated on the same column. Results are resented as mean ± SD from three separate experiments.

Host chaperone proteins and their client proteins are actively involved in viral life cycle. Cyclophilin A (CypA) directly regulated HIV infectivity by interacting with the *N*-terminal domain of HIV-1 capsid protein.[@b0105] CypA also mediated HCV RNA binding to HCV NS5A andstimulated replication of HCV RNA.[@b0110] Hsc70 co-localized with HCV particles in lipid droplet in the infected cells.[@b0070] Hsc70 is also a major chaperone protein participating in the assembly of several subcellular complexes, for example HCV replication complex[@b0030] and RNA-induced silencing complex.[@b0115] The chaperone function of Hsc70 is governed by the *N*-terminal nucleotide binding domain (NBD) with ATPase activity.[@b0120] Mutation of the ATPase pocket abolished the chaperone activity of Hsc70 and its binding to RNA.[@b0125], [@b0130] By promoting the ATPase activity of Hsc70, *rac*-cryptopleurine and DCB-3503 inhibited HCV.[@b0030], [@b0130] Thus, we next determined the impact of cryptopleurine analogs on the ATP/ADP turnover of Hsc70. Addition of *rac*-cryptopleurine enhanced ADP production by promoting the ATPase activity of Hsc70 at 10 µM ([Fig. 2](#f0010){ref-type="fig"}B). The effect on Hsc70 ATPase activity of all cryptopleurine analogs were examined at 10 µM in the same fashion as *rac*-cryptopleurine; only YXM-110 exhibited similar allosteric regulation of Hsc70 ([Fig. 2](#f0010){ref-type="fig"}).

We previously that *rac*-cryptopleurine bound physically but non-covalently to the NBD of Hsc70[@b0030], [@b0130]; therefore, functional analog(s) could interfere with the binding between *rac*-cryptopleurine and Hsc70. We next performed an affinity binding assay using biotinylated-*rac*-cryptopleurine,[@b0030], [@b0130] and eluted Hsc70 bound to the affinity resin with *rac*-cryptopleurine or its analogs. YXM-110, but not YXM-109, YXM-139, nor YXM-140, eluted Hsc70 bound to the affinity resin in the similar fashion as that of *rac*-cryptopleurine ([Fig. 3](#f0015){ref-type="fig"} ). This result together with the result in the ATP/ADP turnover assay suggested that YXM-110, but not other cryptopleurine derivatives, is a functional analog of *rac*-cryptopleurine with similar mechanism(s) of action. YXM-109 and YXM-140 may exhibited anti-HCV activity through other mechanism(s) rather than modulating ATPase activity of Hsc70. Analogs such as YXM-66, YXM-82, YXM-101, YXM-83, YXM-142, and YXM-93 lost the ability to modulate ATPase activity of Hsc70 ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3YXM-110 dissociated binding between biotinylated-*rac*-cryptopleurine and Hsc70. Recombinant Hsc70 was incubated with biotinylated-*rac*-cryptopleurine resin for 2 h at room temperature. Hsc70 bound to the affinity resin were eluted with binding buffer alone or with *rac*-cryptopleurine, YXM-109, YXM-110, YXM-139, YXM-140, respectively. Hsc70 in each sample was resolved by Western blot analysis. Results are representative of two independent experiments.

The turnover of ATP/ADP of Hsc70 is primarily governed by its chaperone activity.[@b0135] Co-chaperone protein nucleotide exchange factor c-terminal of Bag1 (cBag, or Bag-1 M) increased the ATPase activity of Hsc70 in combination with *rac*-cryptopleurine or DCB-3503.[@b0130] We then determined whether *rac*-cryptopleurine and YXM-110 affected luciferase refolding activity of Hsc70. Purified native luciferase was first denatured with 6 M guanidine-HCl and incubated with Hsc70 in the presence or absence of *rac*-cryptopleurine or YXM-110. Luciferase activity was determined using 2 µl aliquot of the reaction mixture at specific time point ([Fig. 4](#f0020){ref-type="fig"} ). The luciferase reactivity was increased in both time- ad dose-dependent manner with the addition of 10 µM or higher concentrations of *rac*-cryptopleurine ([Fig. 4](#f0020){ref-type="fig"}A) and YXM-110 ([Fig. 4](#f0020){ref-type="fig"}B), indicating that these compounds enhanced chaperone activity of Hsc70. The carboxyl terminus Hsc70 interacting protein (CHIP) can enhance the protein refolding activity of Hsc70, thus promote ATP hydrolysis.[@b0135] By promoting the degradation of heat shock protein 70 (Hsp70)-viral coat protein complex in potato virus[@b0140] and Hsp90-viral polymerase complex in mumps virus,[@b0145] CHIP regulated formation of viral replication complex and viral replication.Fig. 4Characterization of effect of cryptopleurine analogs and cochaperone proteins on Hsc70 refolding activity. Relative reactivation of guanidine-denatured luciferase in the presence of difference dosages of (A) *rac*-cryptopleurine, and (B) YXM-110. Relative reactivation of guanidine-denatured luciferase with (C) *rac*-cryptopleurine, and (D) YXM-110 in the presence or absence of recombinant human CHIP. The results are presented as mean ± SD from three independent experiment.

Accordingly, we added recombinant CHIP protein into the luciferase refolding reaction system. Recombinant CHIP by itself did not promote luciferase folding ([Fig. 4](#f0020){ref-type="fig"}C and D), and addition of CHIP alone only marginally promoted luciferase refolding activity of Hsc70 ([Fig. 4](#f0020){ref-type="fig"}C and D). However, the combination of CHIP and *rac*-cryptopleurine or YXM-110 further promoted the luciferase refolding activity of Hsc70 ([Fig. 4](#f0020){ref-type="fig"}C and D).

We next determined whether enhanced Hsc70 chaperone activity was related to the anti-HCV activity of cryptopleurine analogs. We transiently transfected FLAG-tagged CHIP plasmid or empty vector (EV) to Huh-luc/neo-ET cells with cryptopleurine analog treatment. Expression levels of HCV RNA, NS3 and NS5A proteins were downregulated by *rac*-cryptopleurine ([Fig. 5](#f0025){ref-type="fig"} A) or YXM-110 treatment alone ([Fig. 5](#f0025){ref-type="fig"}B). Overexpression of CHIP further enhanced the inhibition of HCV RNA, NS3 and NS5A protein levels, while the expression level of FLAG-CHIP was not changed ([Fig. 5](#f0025){ref-type="fig"}A and B). These results suggested that stoichiometric regulation of Hsc70 by cryptopleurine analogs was related to their anti-HCV activity.Fig. 5Regulation of Hsc70 cochaperone level enhanced anti-HCV activity of *rac*-cryptopleurine and YXM-110. The level of HCV RNA, NS3 and NS5A protein with the treatment of (A) *rac*-cryptopleurine or (B) YXM-110 for 24 h with transient transfection of FLAG-CHIP or empty vector (EV). The results are representative of more than two independent experiments (^\*\*^*p* \< .01; ^\*^*p* \< .05; n.s., nonspecific).

In studies by Lai et al., YXM-110 exhibited anti-tumor activity in HCT116 xenograft model through abrogation of autophagy inhibitor 3-methyladenine and silencing of ATG5,[@b0040] as well as inhibited protein synthesis through proteasome-dependent degradation of 4E-BP1.[@b0040] We previously reported that *rac*-cryptopleurine and YXM-110 inhibited global protein synthesis.[@b0060] Taken together, these results suggest that YXM-110 is a functional analog of *rac*-cryptopleurine, and could be used as a scaffold for future design of cryptopleurine analogs with higher potency against HCV and increased selectivity.

3. Conclusion {#s0015}
=============

We evaluated the inhibitory activity of cryptopleurine analogs with E-ring modifications against HCV replication. Cryptopleurine analogs with different hydroxyl groups (YXM-110, YXM-109, YXM-140) exhibited improved selectivity between anti-HCV activities to cytotoxicity. Analogs with heteroatom modification of the E-ring (YXM-66, YXM-82, and YXM-101) exhibited cytotoxicity, but lost anti-HCV activity. The selectivity of YXM-139 increased compared with *rac*-cryptopleurine; however, the effects against HCV replication and Hsc70 ATPase promotion were diminished. Changing the size of the E-ring (YXM-142, YXM-93) or heteroatom modification (YXM-82) led to total loss of activity. Among all cryptopleurine analogs, YXM-110 exhibited similar anti-HCV activity and allosteric regulation of the ATPase activity of Hsc70 as *rac*-cryptopleurine as well as selectivity against HCV but not HBV ([Fig. 1](#f0005){ref-type="fig"}). Therefore, in addition to *rac*-cryptopleurine, YXM-110 could potentially be used alone or in combination with other anti-HCV regimens to high-barrier-to-resistance HCV infection. Tylophorine analogs like *rac*-cryptopleurine, YXM-110, and DCB-3503 that inhibited proliferation of HepG2 cells could also be used for the treatment of HCV-associated hepatocellular carcinoma.

4. Experimental procedures {#s0020}
==========================

4.1. Materials and reagents {#s0025}
---------------------------

Cell culture media and fetal bovine serum (FBS) were purchased from Invitrogen (Waltham, MA, USA). All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) except for those otherwise noted. YXM compounds were synthesized in Dr. Kuo-Hsiung Lee's laboratory, dissolved in DMSO at 500 μM, and kept as stock solutions.[@b0060]

4.2. Cell lines and growth conditions {#s0030}
-------------------------------------

HCV genotype 1b Con1 subgenomic replicon cell lines Huh-luc/neo-ET containing a luciferase reporter, and Huh 9--13 were provided by Dr. Ralf Bartenschlager from The University of Heidelberg.[@b0150], [@b0155] Huh luc/neo-ET and Huh 9--13 cells were maintained in DMEM medium supplied with 10% FBS (Gibco, Waltham, MA, USA), 1 mM nonessential amino acids (Invitrogen), and 250 µg/ml G418 (Gibco). HepG 2.2.15 cells were cultured in MEME supplemented with 10% FCS (Gibco), and 50 μg/ml kanamycin. All cells were maintained at 37 °C in a humidified 5% CO~2~ atmosphere.

4.3. Determination of anti-HCV activity by luciferase reporter assay {#s0035}
--------------------------------------------------------------------

Firefly-luciferase reporter activity was used to monitor the replication of HCV replicons in Huh-luc/neo-ET cells free from G418.[@b0160] Luciferase activity was measured with a luciferase assay kit (Promega, Madison, Wisconsin, USA) on SpectraMax M5 multi-mode microplate reader (Molecular Devices, Sunnyvale, CA, USA) according to the manufacturer\'s instruction.

4.4. Determination of HBV replication {#s0040}
-------------------------------------

HBV genome integrated HepG 2.2.15 cells were seeded in six-well culture plates at a density of approximately 5 × 10^5^ cells per well. Culture medium was changed every 2 days. Six days after seeding of cells, compounds were added to the cell cultures, and fresh medium was fed every other day for another 6 days. Cells were collected for Southern analysis for viral DNA. Total DNA was isolated by using DNeasy kits (Qiagen, Valencia, CA, USA) following the manufacturer\'s instructions. Twenty micrograms of DNA were separated by electrophoresis with 1% agarose and transferred to Hybond-N^+^ membrane (Amersham Biosciences, Bucks, UK) by using the capillary transfer method with 20 × SSC overnight. After UV-crossing linking, the blot was prehybridized with 1 mg/ml salmon sperm DNA diluted in QuickHyb reagent (Invitrogen) for 1 h at 65 °C. Random ^32^P-labeled HBV full-length probe was then added to the prehybridization reagent and hybridized overnight at 65 °C. The blot was washed with 2 × SSC/0.1% SDS twice for 5 min at room temperature and 0.2 × SSC/0.1 × SDS three times for 20 min at 65 °C. The membrane was exposed to BioMax MR Film (Kodak, Rochester, NY) at − 70 °C overnight or detected by using a PhosphorImager S1 (Molecular Dynamics, Sunnyvale, CA, USA).

4.5. ATP hydrolysis activity assay {#s0045}
----------------------------------

Preparation of recombinant Hsc70 and characterization of the ATP hydrolysis activity of Hsc70 were performed as described previously.[@b0030], [@b0165] Briefly, 0.25 µM Hsc70 was incubated in the presence or absence of various 10 µM compound, ATP, and 0.5 µM HCV wide-type poly U/UC RNA in 50 µl reaction buffer (25 mM MOPS, pH 7.4, 10 mM Mg(OAc)~2~, 30 mM KOAc, 2 mM DTT, 1 mg/ml BSA) at 37 °C for 10 min. The reaction was stopped by adding 45% trichloroacetic acid to a final concentration of 15% (v/v). The aqueous phase was washed with 1,1,2-trichlorotrifluoroethane: trioctylamine (55:45, v/v) twice. The concentration of ADP in the aqueous phase was analyzed by HPLC and determined by the standard curve generated on the same column.

4.6. Affinity purification {#s0050}
--------------------------

The affinity purification was performed as described previously.[@b0130] Huh-luc/neo-ET cells were lysed in protein-binding buffer (PBB, 20 mM Hepes, pH 7.9, 100 mM NaCl, 0.5 mM EDTA, 0.5% Nonidet P-40, 6 mM MgCl~2~, 5 mM 2-mercaptoethanol, complete protease inhibitor (Roche)). Biotinylated-*rac*-cryptopleurine was bound overnight at room temperature to a 50% slurry of streptavidin resin (Invitrogen) in buffer containing 50% DMSO and 50% PBB. Beads were washed to remove unbound compound and then incubated with recombinant Hsc70 in 2.5% BSA. Bound proteins were washed, or eluted with *rac*-cryptopleurine or its analogs. Samples were separated with SDS PAGE, and examined by Western blot.

4.7. Expression and purification of recombinant CHIP {#s0055}
----------------------------------------------------

cDNA of CHIP was cloned using forward primer 5′-ATGAAGGGCAAGGAGGAGAAGGA-3′ and reverse primer 5′-AGACTCTTACCGACCCACCTCCTGATG-3′, and inserted into the NdeI and NotI restriction enzyme sites of pET21b vector with a C-terminal histag. Recombinant proteins were overproduced in *E. coli* BL21 (DE3) pLysS cells (Promega, Madison, WI) at 22 °C for 4 h, purified by Ni^2+^-NTA agarose (Qiagen, Valencia, CA), and dialyzed in 50 mM HEPES/KOH, pH 7.0, containing 50 mM potassium chloride, 5 mM DTT and 10% (v/v) glycerol.

4.8. Luciferase refolding assay {#s0060}
-------------------------------

Refolding of chemically denatured firefly luciferase by Hsc70 in the presence or absence of tylophorine analogs was measured as described previously.[@b0170] Briefly, luciferase was diluted by denaturation buffer (25 mM HEPES, pH 7.4, 50 mM KCl, 5 mM MgCl~2~, 6 M guanidine-HCl, 5 mM DTT) to the final concentration of 5 µM. The denaturation reaction was allowed to proceed for 40 min at 25 °C, and 1 µl aliquot was removed and mixed with 125 µl of refolding buffer (25 mM HEPES, pH 7.4, 50 mM KCl, 5 mM MgCl~2~, 1 mM ATP) that was supplemented with 0.25 µM Hsc70 in the presence or absence of *rac*-cryptopleurine or DCB-3503 in the presence or absence of recombinant CHIP. The refolding reaction was incubated at 25 °C. Aliquots of 4 µl were removed from the folding reactions at the indicated times and luciferase activity was measured.

4.9. Statistical analysis {#s0065}
-------------------------

Data were analyzed by a two-tailed student\'s *t*-test using Prism Graph Pad 5.0. The difference was considered to be statistically significant when *p* \< .05.
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[^1]: EC~50~, the concentration of compound that inhibit 50% of HCV replication relative to vehicle (DMSO) treatment.

[^2]: IC~50~, the concentration of compound that inhibit 50% of cell growth relative to vehicle (DMSO) treatment.

[^3]: EC~10~, the concentration of compound that inhibit 10% of HBV replication relative to vehicle (DMSO) treatment.
